DTwP-HepB-Hib-IPV Hexavalent vaccine

LG Chem is developing a hexavalent combination vaccine (DTwP-HepB-Hib-IPV) to improve vaccine accessibility and affordability in low- and middle-income countries. The market is transitioning from pentavalent vaccines plus separate IPV to hexavalent formulations, thereby reducing immunization visits. While WHO has prioritized hexavalent vaccines for prequalification, limited supply remains a challenge. With previous RIGHT Foundation support, LG Chem scaled production from pilot to commercial scale and established aseptic process validation. This grant supports a Phase II clinical trial in the Philippines to verify improved immunogenicity of a reformulated pertussis component.